261 related articles for article (PubMed ID: 24549101)
1. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
Umbricht D; Keefe RS; Murray S; Lowe DA; Porter R; Garibaldi G; Santarelli L
Neuropsychopharmacology; 2014 Jun; 39(7):1568-77. PubMed ID: 24549101
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
[TBL] [Abstract][Full Text] [Related]
3. The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
Haig G; Wang D; Othman AA; Zhao J
Neuropsychopharmacology; 2016 Nov; 41(12):2893-2902. PubMed ID: 27319970
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
Haig GM; Wang D; Zhao J; Othman AA; Bain EE
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 28922590
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
Haig GM; Bain EE; Robieson WZ; Baker JD; Othman AA
Am J Psychiatry; 2016 Aug; 173(8):827-35. PubMed ID: 26940805
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
[TBL] [Abstract][Full Text] [Related]
7. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
8. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
[TBL] [Abstract][Full Text] [Related]
9. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
[TBL] [Abstract][Full Text] [Related]
10. Calibration and cross-validation of MCCB and CogState in schizophrenia.
Lees J; Applegate E; Emsley R; Lewis S; Michalopoulou P; Collier T; Lopez-Lopez C; Kapur S; Pandina GJ; Drake RJ
Psychopharmacology (Berl); 2015 Nov; 232(21-22):3873-82. PubMed ID: 26018529
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Brown D; Nakagome K; Cordes J; Brenner R; Gründer G; Keefe RSE; Riesenberg R; Walling DP; Daniels K; Wang L; McGinniss J; Sand M
Schizophr Bull; 2019 Mar; 45(2):350-359. PubMed ID: 29718385
[TBL] [Abstract][Full Text] [Related]
12. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
F Egan M; Zhao X; Gottwald R; Harper-Mozley L; Zhang Y; Snavely D; Lines C; Michelson D
Schizophr Res; 2013 May; 146(1-3):224-30. PubMed ID: 23523692
[TBL] [Abstract][Full Text] [Related]
13. Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment.
McCleery A; Ventura J; Kern RS; Subotnik KL; Gretchen-Doorly D; Green MF; Hellemann GS; Nuechterlein KH
Schizophr Res; 2014 Aug; 157(1-3):33-9. PubMed ID: 24888526
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
[TBL] [Abstract][Full Text] [Related]
15. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
[TBL] [Abstract][Full Text] [Related]
16. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
[TBL] [Abstract][Full Text] [Related]
17. Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial.
Smith RC; Amiaz R; Si TM; Maayan L; Jin H; Boules S; Sershen H; Li C; Ren J; Liu Y; Youseff M; Lajtha A; Guidotti A; Weiser M; Davis JM
PLoS One; 2016; 11(1):e0143490. PubMed ID: 26730716
[TBL] [Abstract][Full Text] [Related]
18. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR
Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
Buchanan RW; Keefe RS; Lieberman JA; Barch DM; Csernansky JG; Goff DC; Gold JM; Green MF; Jarskog LF; Javitt DC; Kimhy D; Kraus MS; McEvoy JP; Mesholam-Gately RI; Seidman LJ; Ball MP; McMahon RP; Kern RS; Robinson J; Marder SR
Biol Psychiatry; 2011 Mar; 69(5):442-9. PubMed ID: 21145041
[TBL] [Abstract][Full Text] [Related]
20. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Stauffer VL; Millen BA; Andersen S; Kinon BJ; Lagrandeur L; Lindenmayer JP; Gomez JC
Schizophr Res; 2013 Nov; 150(2-3):434-41. PubMed ID: 24035403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
